VISION Trial (The Phase III Study of Lutetium-177-PSMA-617) Potential Practice-Changing Treatment of mCRPC - ASCO 2021
August 02, 2021
PEER-TO-PEER CLINICAL CONVERSATIONS
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results
Michael Morris, MD
In a plenary presentation at the 2021 ASCO Annual Meeting, Michael Morris presented awaited results of the Phase III VISION trial. The study is evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer compared to best standard of care alone.
177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer in VISION study
Mary-Ellen Taplin, MD
Mary-Ellen Taplin joins Alicia Morgans in a discussion on the therapeutic landscape of metastatic castration-resistant prostate cancer in the context of the positive results reported in the Phase 3 VISION trial.
Highlights from the 2021 American Society of Clinical Oncology Annual Meeting
Phase III Study of Lutetium-177-PSMA-617 in patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
Michael Morris, MD
In a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Michael Morris presented the first results of the VISION trial, a phase III study assessing lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The VISION trial demonstrates that 177Lu-PSMA-617 can be safely added to SOC treatment and improves rPFS and prolongs OS compared with SOC alone in men with advanced-stage PSMA-positive mCRPC, supporting its adoption as a standard of care.
Applying the Results of the Phase III VISION Trial, Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer to Clinical Practice - Discussion
Mary-Ellen Taplin, MD
Mary-Ellen Taplin provided a discussant overview of the VISION trial data and helped to contextualize how we may apply them to our practices. She emphasized that the VISION trial met both of its primary endpoints and showed that lutetium-177-PSMA-617 + SOC significantly improved overall and radiographic progression-free survival, as well as many other secondary endpoints.
How to Rationally Incorporate Metastasis-Directed Therapy into Your Practice
Chair: Howard M. Sandler, MD
Panelists: Phuoc T. Tran, MD, Ph.D., Nicholas D. James, MBBS, Ph.D. and Robert Given, MD
A case-based panel discussion on oligometastases in prostate cancer was moderated by Dr. Howard M. Sandler. Dr. Phuoc Tran offered the radiation oncologist’s perspective, Dr. Nicholas James offered an international perspective, and Dr. Robert Given provided the community perspective. Several cases were presented and the panel presented various perspectives on how to rationally incorporate detastasis-directed therapy into your practice
Diagnostic Performance of Ga-68 PSMA PET/CT Imaging In Early-Relapsed Prostate Cancer: Phase 3, Prospective, Multicenter Study (IAEA-PSMA study)
Juliano Cerci, MD, Ph.D.
Juliano Cerci presented the results of this phase 3 trial.
In this trial, patients with prostate cancer who have undergone primary definitive treatment and with rising PSA were recruited in the study. Overall 17 centers from 15 countries (Azerbaijan, Brazil, Colombia, India, Israel, Italy, Jordan, Lebanon, Malaysia, Mexico, Pakistan, Poland, South Africa, Turkey, and Uruguay) were involved.
Results of an Ongoing Phase 1/2a Dose Escalation Study of HPN424, a Tri-Specific Half-Life Extended PSMA-Targeting T-Cell Engager, in Patients with mCRPC
Johann de Bono, MD, MSc, PhD, FRCP, FMedSci
Johann de Bono presented initial results of the ongoing phase 1/2a HPN424-1001 trial assessing HPN424 in mCRPC patients. HPN424, a novel half-life extended PSMA-targeting T cell engager, is active and generally well tolerated when administered once weekly.
COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC
Mark Markowski, MD
Mark Markowski reported results of a prospective phase 2 study of men with mCRPC treated with BAT in combination with nivolumab. This was a multi-center, single arm, open label phase 2 trial of men with mCRPC who received testosterone cypionate 400mg intramuscular (BAT) every 28 days and nivolumab 480mg IV every 28 days, during which time LHRH agonist treatment was continued.
Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191
Neha Vapiwala, MD, FACR
Neha Vapiwala presented the trial design of INDICATE, a study that will evaluate whether patients with PET-detected lesions benefit from such local or systemic treatment intensification approaches. The primary endpoint is PFS, defined as time from randomization to radiographic progression on conventional imaging, symptomatic disease or death. Primary objectives are to evaluate whether addition of apalutamide to standard of care salvage therapy and addition of metastasis-directed radiotherapy to standard of care salvage therapy and apalutamide could prolong PFS in Cohorts 1 and 2, respectively.
Phase I Study of CCW702, A Bispecific Small Molecule-Antibody Conjugate Targeting PSMA and CD3 in Patients with mCRPC
Mark Markowski, MD
Mark Markowski presented trial design of this first-in-human, open-label, multi-center phase 1 study evaluating the safety and tolerability of CCW702 when administered via subcutaneous injection in men with mCRPC. This study will enroll 20-30 patients in Part 1 and approximately 40 patients in Part 2. The study opened in December 2019 and is currently enrolling in the dose escalation phase at the following site: Johns Hopkins University, Karmanos Cancer Institute (Detroit, MI), Medical College of Wisconsin, University of California San Diego, and University of Virginia.